Cargando…
Mebendazole Treatment Disrupts the Transcriptional Activity of Hypoxia-Inducible Factors 1 and 2 in Breast Cancer Cells
SIMPLE SUMMARY: Mebendazole (MBZ), an orally available, FDA-approved anthelmintic, has demonstrated efficacy in reducing solid tumor growth and preventing or treating metastasis in multiple preclinical models of cancer. MBZ was also well tolerated in a recently completed phase I clinical trial. Give...
Autores principales: | Joe, Natalie S., Wang, Yuanfeng, Oza, Harsh H., Godet, Inês, Milki, Nubaira, Riggins, Gregory J., Gilkes, Daniele M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954103/ https://www.ncbi.nlm.nih.gov/pubmed/36831670 http://dx.doi.org/10.3390/cancers15041330 |
Ejemplares similares
-
Mebendazole prevents distant organ metastases in part by decreasing ITGβ4 expression and cancer stemness
por: Joe, Natalie S., et al.
Publicado: (2022) -
Mebendazole disrupts stromal desmoplasia and tumorigenesis in two models of pancreatic cancer
por: Williamson, Tara, et al.
Publicado: (2021) -
The Rate of Cisplatin Dosing Affects the Resistance and Metastatic Potential of Triple Negative Breast Cancer Cells, Independent of Hypoxia
por: Bhatavdekar, Omkar, et al.
Publicado: (2022) -
Preventative Effect of Mebendazole against Malignancies in Neurofibromatosis 1
por: Staedtke, Verena, et al.
Publicado: (2020) -
Detection of Hypoxia in Cancer Models: Significance, Challenges, and Advances
por: Godet, Inês, et al.
Publicado: (2022)